Evaluate the Ability of Systane Ultra to Improve Subjective Symptoms of Ocular Irritation Post 60 Min. Athletic Performance.

Visual Performance Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00938951
• Other study ID #: SMA-09-22
• Status: Completed
• Phase: N/A
• First received: July 13, 2009
• Last updated: February 8, 2012
• Start date: June 2009

Study information

• Verified date: February 2012
• Source: Alcon Research
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to compare visual degradation in a stressed (forced stare) environment in patients before and after acute administration of Systane Ultra.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. primary completion date: July 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Player/ Coach must answer "Yes" to the survey eligibility question.

• Player/Coach must voluntarily agree to participate in survey

Exclusion Criteria:

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Dry Eye Symptoms
• Visual Performance

Intervention

Other:
• Systane® Ultra
Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alcon Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of eye drop basd on athlete's opinion/experience during a one hour practice session		60 minutes post-dosing with test article	No